Polytheragene has specific know-how in the synthesis of polymers for biology. Polytheragene commercializes PTG1 for the transfer of nucleic acids.
The company targets companies involved in the bioproduction of proteins and recombinant viral particles, screening platforms and research laboratories.
Polytheragene invests in gene therapy and mRNA-based therapies.
